Histology and spatial transcriptomic integration revealed infiltration zone with specific cell composition as a prognostic hotspot in glioblastoma
Lucas FidoniD, Mélanie LubranoiD, Caroline HoffmanniD, Esther BaenaiD, Céline Thiriez, Luis CanoiD, Alex J. CornishiD, Elo MadissooniD, Valérie DucretiD, Christian Esposito, Auriane Riou, Eric Y. DurandiD, Benoît SchmauchiD, Elodie Pronier, Alberto RomagnoniiD, Almudena Espín-PéreziD, Markus EcksteiniD, Raphaël GottardoiD, Theoni MaragkouiD, Mohamed ShelaniD, Almoatazbellah YoussefiD, Spencer S. WatsoniD, Marc SansoniD, Franck BielleiD
Abstract
BackgroundGlioblastoma (GBM), the most aggressive primary brain tumor, has a median survival of approximately 15 months. Twenty percent of patients survive beyond three years, but known clinical factors like age, performance status, resection extent, and MGMT promoter methylation status do not fully explain the observed outcomes. ObjectiveOur objective was to identify novel histology derived biomarkers associated with end-of-spectrum overall survival (OS) to provide novel biological insight with a translational potential. MethodsWe analyzed a total of 748 GBM patients from 3 different cohorts, uniquely enriched in long survivors (n=98 with overall survival (OS) > 5y including n=196 with OS[≥]3y), with clinical data and H&E slides obtained from the primary tumor at baseline. We propose an interpretable machine learning (ML) methodology for the discovery of histological biomarkers. Our method learned to segment each H&E slide into three distinct regions associated with long-term survival, short-term survival, and non-informative tissue. We characterized these regions by integrating unsupervised learning, nuclei segmentation, blood vessels detection, pathologist annotations, and multimodal data including spatial transcriptomics from n=31 patients of the GBM MOSAIC dataset to discover fully interpretable biomarkers. ResultsOur OS prediction model using histology and clinical data as input achieved an area under the curve (AUC) of 0.85 for the classification of patients between OS View larger version (43K): org.highwire.dtl.DTLVardef@45e619org.highwire.dtl.DTLVardef@105a4b0org.highwire.dtl.DTLVardef@17f257dorg.highwire.dtl.DTLVardef@7669b4_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multiple instance learning with spatial transcriptomics for interpretable patient-level predictions: application in glioblastoma
Simon Grouard, Christian Esposito, … Lucas Fidon·bioRxiv·Oct 13, 2025
- Screening of Cellular Senescence Related Genes as Biomarkers and Therapeutic Targets for Glioblastoma by Integrated Machine Learning
Tianle Xue, Yufan Hu, … Tian Xie·bioRxiv·Aug 19, 2025
- Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology
Zezhong Ye, Richard L. Price, … Sheng‐Kwei Song·Clinical Cancer ResearchPeer-reviewed·Jul 21, 2020
- Local Tumor Microenvironment Niches Correlate with Survival and Immunotherapy Response in Human Glioblastoma
Florent Petitprez, Nicola Graham, … Jeffrey W. Pollard·bioRxiv·Sep 17, 2026
- Spatially Integrated Multi-Omics reveals the Multicellular Landscape of Progenitor-Driven Glioblastoma Progression
Korbinian Traeuble, Jakob Träuble, … Matthias Heinig·bioRxiv·Feb 28, 2026
- Overall patient's survival of glioblastoma associated to molecular markers: a pan-proteomic prospective study
L. Drelich, M. Duhamel, … M. Salzet·bioRxiv·Nov 24, 2020